Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.

The oncologist - 8 Jul 2026

Liu Chaoxing, Li Kang, Feng Jingjian

Abstract excerpt

KRAS G12C mutations are rare in intrahepatic cholangiocarcinoma (iCCA), occurring in approximately 1% of cases. While adagrasib has shown efficacy in biliary tract cancers in clinical trials, real-world evidence for sotorasib remains limited. We report a 64-year-old male with advanced iCCA harboring a KRAS p.(G12C) mutation (58.07% allelic frequency) who progressed on multiple prior therapies including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Cholangiocarcinoma
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 42405535
DOI: 10.1093/oncolo/oyag260
PMCID: PMC13368809

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.PMID 42405535Read ↗

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read ↗

Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib.Semantic proximity Read ↗

Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation.Semantic proximity Read ↗

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.Semantic proximity Read ↗

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read ↗

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.Semantic proximity Read ↗

Sotorasib as Fourth-Line Treatment in Pancreatic Cancer: A Case Report and Literature Review.Semantic proximity Read ↗

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.Semantic proximity Read ↗

A case of hepatoid adenocarcinoma of the lung harboring KRAS G12C responded favorably to sotorasib.Semantic proximity Read ↗

Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center StudySemantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.